Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FXH vs FXO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FXO Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

FXO Overall Winner 6-Pillar Tally: FXH 0 – 0 FXO (6 Tie) Matrix Metrics: FXH 1 – 2 FXO

As of Nov 16, 2026, First Trust Financials AlphaDEX Fund (FXO) is the stronger overall head-to-head candidate over First Trust Health Care AlphaDEX Fund (FXH) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). FXH carries a Unified Composite Score of 48.7/100 (HOLD) at $136.68 (N/M Forward P/E, N/A operating margin), whereas FXO carries 46.3/100 (HOLD) at $65.45 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While FXH currently prints a higher short-term Unified Composite Score (48.7/100 HOLD vs. FXO 46.3/100 HOLD), FXO captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FXH vs FXO
FXH NYSE Arca
First Trust Health Care AlphaDEX Fund
Institutional Equity
$136.68
-1.11% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.57β · 25% Vol
Unified Composite Score
48.7 / 100 HOLD
Tech 42.0 Fund 44.0 Flow 50.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.3% over 20 days), RSI 53
RSI-14: 52.7 · SMA20: $137.44 · SMA50: $133.45
FXO NYSE Arca Head-to-Head Winner
First Trust Financials AlphaDEX Fund
Institutional Equity
$65.45
-0.58% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.39β · 18% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 37.0 Fund 43.0 Flow 50.0 Mom 41.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.1 · SMA20: $64.87 · SMA50: $63.58

6-Pillar Scorecard Institutional Category Breakdown (FXH 0 – 0 FXO)

Columns: Metric · FXH · FXO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 22.8% (85th %ile) 19.5% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FXH (1) vs FXO (2)
Institutional Metric FXH FXO Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
82% ($105–$144) 85% ($54–$67) Stronger Trend FXO
Beta / 30D Volatility
Risk Regime
0.57β · 25% Vol 0.39β · 18% Vol Lower Realized Risk FXO
Unified Institutional Score
Composite Signal
48.7 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite FXH
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FXO +0.68 pp
FXH: +3.21% · FXO: +3.89%
3M Horizon FXH +4.63 pp
FXH: +3.47% · FXO: -1.16%
6M Horizon FXH +9.91 pp
FXH: +20.6% · FXO: +10.69%
1Y Horizon FXH +9.45 pp
FXH: +21.77% · FXO: +12.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FXH vs FXO. Trailing 12-month operating profitability (FXH N/A vs FXO N/A) and valuation multiples (FXH N/M vs FXO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

FXH ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
FXO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FXH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.8%
IV Percentile 85th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FXH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FXO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 19.5%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FXO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FXH Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FXO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FXH vs FXO Key Questions & Quantitative Answers

As of Nov 16, 2026, First Trust Financials AlphaDEX Fund (FXO) is the stronger overall head-to-head candidate over First Trust Health Care AlphaDEX Fund (FXH) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). FXH carries a Unified Composite Score of 48.7/100 (HOLD) at $136.68 (N/M Forward P/E, N/A operating margin), whereas FXO carries 46.3/100 (HOLD) at $65.45 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While FXH currently prints a higher short-term Unified Composite Score (48.7/100 HOLD vs. FXO 46.3/100 HOLD), FXO captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).

FXH and FXO split Growth & Scale metrics: FXH posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with FXO at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, FXH generates N/A in USD-normalized revenue versus N/A for FXO. In operating R&D and SG&A reinvestment, FXH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FXO.

FXH and FXO trade at balanced relative valuation multiples. FXH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas FXO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FXH (N/A ROE) versus FXO (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, FXH carries 22.8% implied volatility (85th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.57β · 25% Vol realized risk). By comparison, FXO carries 19.5% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 18% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.